Novartis’ Cosentyx has strong Phase 3 interim showing in axial spondyloarthritis

pharmafile | September 17, 2019 | News story | Manufacturing and Production, Research and Development Cosentyx, Novartis, pharma 

Novartis has highlighted new data from its ongoing Phase 3 trial into the efficacy and safety of itsinterleukin-17A inhibitor Cosentyx (secukinumab) in the treatment of non-radiographic axial spondyloarthritis (nr-axSpA), showing that the drug met its primary endpoint and all secondary endpoints.  

Foremost among the results was the finding that, after 16 weeks, patients using Cosentyx achieved a score of 40% on the Assessment of SpondyloArthritis international Society scale, representing a “significant and clinically meaningful reduction in disease activity” compared to placebo, and meeting the trial’s primary endpoint.

The drug’s safety profile was also found to be positive, in line with previous studies.

“These study results for Cosentyx build on our long-standing experience in ankylosing spondylitis and are a step toward a new treatment option that could allow patients to realize relief much earlier in axial spondyloarthritis,” said Dr John Tsai, Head of Global Drug Development and Chief Medical Officer for Novartis. “If approved, this would be the fourth indication for Cosentyx.”

Novartis confirmed it plans to present full data from the study at an upcoming scientific congress.

Matt Fellows

Related Content

Novartis shares new data about Fabhalta for IgAN treatment

Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …

chuttersnap-oijvdm3zx4i-unsplash

Novartis shares new data for Zolgensma in children with SMA

Novartis has announced new data to continue the support of the clinical benefits of Zolgensma …

Novartis to acquire MorphoSys AG for €2.7bn

Novartis has announced that it has entered an agreement to acquire MorphoSys AG for €2.7bn, …

Latest content